Reduction and Escalation in the Dose of Sunitinib Were Adequately Effective against Gastrointestinal Stromal Tumor of the Small Intestine

Misato Ogata; Hironaga Satake; Takatsugu Ogata; Yukimasa Hatachi; Shigeo Hara; Seiichi Hirota; Hisateru Yasui

doi:10.2169/internalmedicine.2806-19

CASE REPORTS

Reduction and Escalation in the Dose of Sunitinib Were Adequately Effective against Gastrointestinal Stromal Tumor of the Small Intestine

Misato Ogata, Hironaga Satake, Takatsugu Ogata, Yukimasa Hatachi, Shigeo Hara, Seiichi Hirota, Hisateru Yasui

Author information

Misato Ogata
Department of Medical Oncology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Japan
Hironaga Satake
Department of Medical Oncology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Japan
Cancer Treatment Center, Kansai Medical University Hospital, Japan
Takatsugu Ogata
Department of Medical Oncology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Japan
Yukimasa Hatachi
Department of Medical Oncology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Japan
Shigeo Hara
Department of Pathology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Japan
Seiichi Hirota
Department of Surgical Pathology, Hyogo College of Medicine, Japan
Hisateru Yasui
Department of Medical Oncology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Japan

Keywords: gastrointestinal stromal tumor, sunitinib, dose modification

JOURNAL OPEN ACCESS

2019 Volume 58 Issue 22 Pages 3243-3246

DOI https://doi.org/10.2169/internalmedicine.2806-19

Browse “Advance online publication” version

Details

Abstract

We herein report the first case in which an escalated dose of sunitinib was effective, even after dose reduction. A 64-year-old man with gastrointestinal stromal tumor of the small intestine discontinued adjuvant imatinib because of interstitial pneumonia. After two years, peritoneal recurrence was detected. Sunitinib was started at 50 mg/day for 4 weeks every 6 weeks, after which the dosage was reduced to 37.5 mg/day because of grade 1 gastritis, stomatitis, and a fever. Four months later, computed tomography showed progressive disease. As the adverse events were well-controlled by medication, we escalated the dose to 50 mg/day and achieved a partial response.

Corresponding author

Register with J-STAGE for free!